Literature DB >> 1253627

Comparative pharmacokinetic studies of ornidazole and metronidazole in man.

D E Schwartz, F Jeunet.   

Abstract

Pharmacokinetic characteristics of ornidazole and metronidazole were compared in man. Both drugs were labelled with 14C in the imidazole ring at position 2. Four healthy volunteers were given an oral dose of 750 mg of one of the drugs, followed 2--4 weeks later by the same dose of the other. The same technique for determining the unchanged compound was used for both drugs. Results may be summarized as follows: mean peak concentrations in the plasma of 10.9 mug/ml for ornidazole and of 12.3 mug/ml for metronidazole were reached 2--4 h and 30--60 min after administration, respectively; both drugs showed the same volume of distribution. Their binding to human plasma proteins was less than 15%; the mean half-life of elimination from the plasma was 14.4 h for ornidazole and 8.4 h for metronidazole; the mean radioactivity recovered from the urine and faeces during the first 5 days was 85% of the dose for ornidazole and 91% for metronidazole, the major proportion in each case being excreted in the urine; the radioactivity found in the faeces was 22.1% of the dose for ornidazole and 13.9% for metronidazole.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1253627     DOI: 10.1159/000221906

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  22 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Plasma levels after a single oral dose of 1.5 g ornidazole.

Authors:  I Matheson; K H Johannessen; B Bjorkvoll
Journal:  Br J Vener Dis       Date:  1977-08

3.  High haemodialysis clearance of ornidazole in the presence of a negligible renal clearance.

Authors:  F F Horber; O Maurer; P J Probst; E Heizmann; F J Frey
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Pharmacokinetics of ornidazole in neonates and infants after a single intravenous infusion.

Authors:  A Turcant; J C Granry; P Allain; M Cavellat
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Bioavailability of metronidazole in fasting and non-fasting healthy subjects and in patients with Crohn's disease.

Authors:  A Melander; G Kahlmeter; C Kamme; B Ursing
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

6.  Relation between concentrations of metronidazole and Bacteroides spp in faeces of patients with Crohn's disease and healthy individuals.

Authors:  A Krook; B Lindström; J Kjellander; G Järnerot; L Bodin
Journal:  J Clin Pathol       Date:  1981-06       Impact factor: 3.411

7.  Influence of dose and route of administration on disposition of metronidazole and its major metabolites.

Authors:  S Loft; M Døssing; H E Poulsen; J Sonne; K L Olesen; K Simonsen; P B Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors.

Authors:  P E Noker; L Simpson-Herren; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 9.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.